Jan 15, 2021
Death benefit not seen in patients on mechanical ventilation
Among patients hospitalized with Covid-19 not receiving mechanical ventilation, treatment with high-titer convalescent plasma was associated with a lower risk for death than those receiving plasma with low antibody, according to peer-reviewed findings from a retrospective analysis of more than 3,000 patients.
In addition, patients who received convalescent plasma very early – within 3 days of receiving a diagnosis of Covid-19 – had a lower risk of death than those who received the treatment later in the disease course.
Findings from the study of patients enrolled in the Mayo Clinic’s Covid-19 Convalescent Plasma Extended-Access Program were published ahead of peer review in mid-August, and they were instrumental in the decision by the U.S. Food and Drug Administration to grant emergency-use authorization (EUA) status for convalescent plasma for the treatment of adults hospitalized with Covid-19.